GlassScriptPhysician profile
Bryan J Vekovius
NPI 1285674820
$29,439.08
in general payments reported to CMS, 2019-2025
35 companies · $3,037 in 2025
The $3,037 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $1,304 · 2021: $3,782 · 2022: $2,556 · 2023: $6,678 · 2024: $11K · 2025: $3,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $5,100 · Honoraria: $3,150 · Travel and Lodging: $1,534 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $638 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,266.22 |
| Consulting Fee | $5,100.00 |
| Honoraria | $3,150.00 |
| Travel and Lodging | $1,533.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $637.50 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $8,459.63 | 2022-2025 | Tepezza, Uplizna, Aimovig |
| Horizon Therapeutics Plc | $7,670.66 | 2020-2023 | Uplizna, Tepezza |
| Alexion Pharmaceuticals, INC. | $1,743.91 | 2019-2025 | Ultomiris, Soliris |
| Merz North America, INC. | $932.63 | 2019-2025 | |
| Abbvie INC. | $904.84 | 2022-2025 | Ozurdex, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $887.25 | 2019-2025 | Cequa |
| Argenx US, INC. | $832.57 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $831.61 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $725.36 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $705.51 | 2021-2025 | Acthar |
| Ucb, INC. | $686.62 | 2023-2025 | Zilbrysq, Rystiggo |
| Oyster Point Pharma, INC. | $652.72 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $611.10 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $464.16 | 2019-2022 | |
| Biotissue Holdings INC. | $421.40 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $386.99 | 2024-2025 | Xdemvy |
| Merz Pharmaceuticals, LLC | $381.66 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $303.20 | 2019-2021 | |
| Alimera Sciences, INC. | $286.08 | 2024 | Iluvien, Yutiq |
| Harrow Eye, LLC | $247.80 | 2024-2025 | Vevye |
| Alcon Vision LLC | $222.24 | 2019-2025 | Rocklatan, Eysuvis, Tryptyr |
| Pfizer INC. | $154.73 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $138.72 | 2024-2025 | Purified Cortrophin Gel |
| Springworks Therapeutics, INC. | $135.51 | 2025 | Gomekli |
| Shire North American Group INC | $125.86 | 2019 | |
| Apellis Pharmaceuticals, INC. | $112.20 | 2023-2024 | Syfovre |
| Lundbeck LLC | $98.56 | 2024-2025 | Vyepti |
| Janssen Biotech, INC. | $80.25 | 2025 | |
| Galderma Laboratories, L.P. | $76.96 | 2021-2023 | Dysport |
| Aerie Pharmaceuticals, INC. | $58.59 | 2019-2020 | |
| Axogen | $25.22 | 2021 | |
| Genentech USA, INC. | $24.81 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $15.96 | 2025 | Iyuzeh |
| Glaukos Corporation | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Vekovius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.